1 / 52

IOF International Osteoporosis Foundation Cooper C Ebeling PR Eastell R Silverman S Vasikaran S

IOF International Osteoporosis Foundation Cooper C Ebeling PR Eastell R Silverman S Vasikaran S . Clinical Needs In Osteoporosis. Bone Remodelling Cycle. Age Dependency Patterns In Women. Classification of BTMs. Attractiveness of BTMs. Limitations of BTMs.

illias
Download Presentation

IOF International Osteoporosis Foundation Cooper C Ebeling PR Eastell R Silverman S Vasikaran S

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IOF International Osteoporosis FoundationCooper CEbeling PREastell RSilverman SVasikaran S

  2. Clinical Needs In Osteoporosis

  3. Bone Remodelling Cycle

  4. Age Dependency Patterns In Women

  5. Classification of BTMs

  6. Attractiveness of BTMs

  7. Limitations of BTMs

  8. Uncontrollable Sources of Pre-analytical Variability

  9. Controllable Sources of Pre-analytical Variability

  10. Seasonal Variability

  11. Diurnal Variation in Urine Dpd

  12. Diurnal Variation in Serum CTX

  13. BTMs Predict Fracture Independently of BMD

  14. The Additive Effects of BTMs and BMD on Fracture Risk

  15. BTMs Predict Fracture Independently of Prior Fracture

  16. Markers of Bone Formation and Prediction of Fracture

  17. Limitations

  18. Limitations (2)

  19. Predictive Capacity of BTMs Attenuates with Time

  20. BTMs in Fracture Risk Algorithms

  21. sCTX and Fracture Prediction in Postmenopausal Women

  22. sP1NP and Fracture Prediction in Postmenopausal Women

  23. Relationship Between Bone Turnover and Bone Loss

  24. Typical BTM Changes After Anti-Resorptive vs Anabolic Therapy

  25. Response of BTMs To Anabolic Therapy (hPTH1-34)

  26. Response of BTMs to Strontium Ranelate

  27. Dose Response of Serum CTX With Ibandronate

  28. Frequency of Administration of an Anti-Resorptive TherapyDaily vs. monthly risedronate

  29. Route of Administration Determines BTM Response

  30. Wide Variability of Changes in BTM After Therapy

  31. Effects of Discontinuing Alendronate on sCTX and BSAP

  32. Effects of Discontinuing Denosumab on Serum CTX and BSAP

  33. Effect of Denosumab Re-treatment on Serum CTX and BSAP

  34. Baseline sCTX and P1NP Predict Change in BMD with Alendronate or Denosumab Therapy

  35. Changes in BTMs After Treatment Correlate With Fracture Risk Reduction

  36. Percent of Treatment Effect Explained by Bone Turnover Markers

  37. BTM vs BMD Monitoring

  38. Evidence for the Utility of Bone Turnover Markers In Monitoring Osteoporosis Treatment

  39. BMD vs BTMs for Monitoring

  40. BTMs Vary With Age In Premenopausal Women

  41. Reference Intervals For sCTX

  42. Reference Inetrvals For sP1NP

  43. « Drug Holidays »

  44. Algorithm For Drug Holidays

  45. BTMs Could Identify Secondary Osteoporosis

  46. BTMs Could Predict the Response to Therapy

  47. BTMs Could Improve Adherence to Treatment

  48. IOF-IFCC Recommendations

  49. IOF-IFCC Recommendations

  50. sCTX: Reference Standard for Bone Resorption

More Related